The Keri Lab has a record of publishing research in high-impact peer-reviewed journals. Below are the 5 most recent publications from our lab. The National Center for Biotechnology Information contains an up-to-date list of all of our publications.
LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance. Roberts MS, Sahni JM, Schrock MS, Piemonte KM, Weber-Bonk KL, Seachrist DD, Avril S, Anstine LJ, Singh S, Sizemore ST, Varadan V, Summers MK, Keri RA. Cancer Res. 2020 Feb 13. doi:10.1158/0008-5472.CAN-19-3466
A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis. Anstine LJ, Keri RA. J Cancer Metastasis Treat. 2019 Jun 13. doi: 10.20517/2394-4722.2019.24.
The Activin Social Network: Activin, Inhibin and Follistatin in Breast Development and Cancer. Seachrist DD, Keri RA. Endocrinology. 2019 Mar 15; 160(5):1097-1110. doi: 10.1210/en.2019-00015.
Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA. J Biol Chem. 2018 Nov 27. doi: 10.1074/jbc.RA118.004712.
Targeting bromodomain and extraterminal proteins in breast cancer. Sahni JM, Keri RA. Pharmacol Res. 2018 Mar; 129:156-176. doi: 10.1016/j.phrs.2017.11.015.